TY - JOUR
T1 - rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology
AU - Australian Ovarian Cancer Study Group
AU - Ovarian Cancer Association Consortium
AU - Kelemen, Linda E.
AU - Earp, Madalene
AU - Fridley, Brooke L.
AU - Chenevix-Trench, Georgia
AU - Fasching, Peter A.
AU - Beckmann, Matthias W.
AU - Ekici, Arif B.
AU - Hein, Alexander
AU - Lambrechts, Diether
AU - Lambrechts, Sandrina
AU - Van Nieuwenhuysen, Els
AU - Vergote, Ignace
AU - Rossing, Mary Anne
AU - Doherty, Jennifer A.
AU - Chang-Claude, Jenny
AU - Behrens, Sabine
AU - Moysich, Kirsten B.
AU - Cannioto, Rikki
AU - Lele, Shashikant
AU - Odunsi, Kunle
AU - Goodman, Marc T.
AU - Shvetsov, Yurii B.
AU - Thompson, Pamela J.
AU - Wilkens, Lynne R.
AU - Dörk, Thilo
AU - Antonenkova, Natalia
AU - Bogdanova, Natalia
AU - Hillemanns, Peter
AU - Runnebaum, Ingo B.
AU - Bois, Andreas Du
AU - Harter, Philipp
AU - Heitz, Florian
AU - Schwaab, Ira
AU - Butzow, Ralf
AU - Pelttari, Liisa M.
AU - Nevanlinna, Heli
AU - Modugno, Francesmary
AU - Edwards, Robert P.
AU - Kelley, Joseph L.
AU - Ness, Roberta B.
AU - Karlan, Beth Y.
AU - Lester, Jenny
AU - Orsulic, Sandra
AU - Walsh, Christine
AU - Kjaer, Susanne K.
AU - Jensen, Allan
AU - Cunningham, Julie M.
AU - Vierkant, Robert A.
AU - Giles, Graham G.
AU - Goode, Ellen L.
N1 - Funding Information:
The Collaborative Oncology Gene-environment Study project is funded through a European Commission’s Seventh Framework Programme grant (agreement number 223175-HEALTH-F2-2009-223175). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project was supported by the Canadian Institutes of Health Research (MOP-86727) and the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). Funding of the constituent studies was provided by the American Cancer Society (CRTG-00-196-01-CCE); the California Cancer Research Program (00-01389V-20170, N01-CN25403, 2II0200); the Canadian Institutes for Health Research (MOP-86727); Cancer Council Victoria; Cancer Council Queensland; Cancer Council New SouthWales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A16561, C490/A6187, C490/A10119, C490/A10124, C536/A13086, C536/A6689); the Celma Mastry Ovarian Cancer Foundation; the Danish Cancer Society (94-222-52); the ELAN Program of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Hospital Research Fund; Helse Vest; Imperial Experimental Cancer Research Centre (C1312/A15589); the Norwegian Cancer Society; the Norwegian Research Council; the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health Labour and Welfare of Japan; Grants-in-Aid for Scientific Research on Priority Areas and Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Science, Sports, Culture and Technology of Japan; Takeda Science Foundation; the L and S Milken Foundation; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation; the Roswell Park Cancer Institute Alliance Foundation; the US National Cancer Institute (K07-CA095666, K22-CA138563, N01-CN55424, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P30-CA15083, P30-CA008748, P50-CA105009, P50- CA136393, P50-CA159981, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01- CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063678, R01-CA063682, R01-CA064277, R01-CA067262, R01- CA071766, R01-CA074850, R01-CA076016, R01-CA080742, R01-CA080978, R01-CA083918, R01-CA087538, R01- CA092044, R01-095023, R01-CA106414, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01- CA136924, R01-CA149429, R03-CA113148, R03-CA115195, R37-CA070867, R37-CA70867, U01-CA069417, U01- CA071966, UM1 CA186107, UM1 CA176726 and Intramural research funds); the US Army Medical Research and Material Command (DAMD17-98-1-8659, DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-10-1-0280, W81XWH-07-0449); the National Health and Medical Research Council of Australia (199600 and 400281); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01 GB 9401); the German Cancer Research Center (DKFZ); the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the Lon V. Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College Hospital “Womens Health Theme”, the Royal Marsden Hospital; WorkSafeBC, and OvCaRe: British Columbia’s Ovarian Cancer Research Team. L.E.K. was supported by a Canadian Institutes of Health Research Investigator award (MSH-87734). G.C.-T. is supported by the National Health and Medical Research Council. B.K. is supported by an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS) Grant (UL1TR000124). F.M. is supported by a K-award from the National Cancer Institute (K07-CA080668). A.L. was supported by a T32 training grant from the US National Institute of Environmental Health Sciences (T32ES013678).
Publisher Copyright:
© 2018 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2018/9
Y1 - 2018/9
N2 - Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97-1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03-1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
AB - Thymidylate synthase (TYMS) is a crucial enzyme for DNA synthesis. TYMS expression is regulated by its antisense mRNA, ENOSF1. Disrupted regulation may promote uncontrolled DNA synthesis and tumor growth. We sought to replicate our previously reported association between rs495139 in the TYMS-ENOSF1 3′ gene region and increased risk of mucinous ovarian carcinoma (MOC) in an independent sample. Genotypes from 24,351 controls to 15,000 women with invasive OC, including 665 MOC, were available. We estimated per-allele odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression, and meta-analysis when combining these data with our previous report. The association between rs495139 and MOC was not significant in the independent sample (OR = 1.09; 95% CI = 0.97-1.22; p = 0.15; N = 665 cases). Meta-analysis suggested a weak association (OR = 1.13; 95% CI = 1.03-1.24; p = 0.01; N = 1019 cases). No significant association with risk of other OC histologic types was observed (p = 0.05 for tumor heterogeneity). In expression quantitative trait locus (eQTL) analysis, the rs495139 allele was positively associated with ENOSF1 mRNA expression in normal tissues of the gastrointestinal system, particularly esophageal mucosa (r = 0.51, p = 1.7 × 10−28), and nonsignificantly in five MOC tumors. The association results, along with inconclusive tumor eQTL findings, suggest that a true effect of rs495139 might be small.
KW - Consortia
KW - Enolase superfamily member 1
KW - Expression quantitative trait locus
KW - Genetics
KW - Gynecology
KW - Ovarian neoplasms
KW - Single-nucleotide polymorphism
KW - Thymidylate synthase
UR - http://www.scopus.com/inward/record.url?scp=85052837195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052837195&partnerID=8YFLogxK
U2 - 10.3390/ijms19092473
DO - 10.3390/ijms19092473
M3 - Article
C2 - 30134598
AN - SCOPUS:85052837195
SN - 1661-6596
VL - 19
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 9
M1 - 2473
ER -